KR960004367A - α1-안티카이모트립신의 제조방법 - Google Patents
α1-안티카이모트립신의 제조방법 Download PDFInfo
- Publication number
- KR960004367A KR960004367A KR1019950022667A KR19950022667A KR960004367A KR 960004367 A KR960004367 A KR 960004367A KR 1019950022667 A KR1019950022667 A KR 1019950022667A KR 19950022667 A KR19950022667 A KR 19950022667A KR 960004367 A KR960004367 A KR 960004367A
- Authority
- KR
- South Korea
- Prior art keywords
- act
- iii
- conductivity
- antichymotrypsin
- contacting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
본 발명은 크로마토그래피 흡착 단계를 사용하여 조심스럽게 조절된 pH와 전도도에서 사람 α1-프로테이나제 억제제(PI) 및 안티트롬빈 Ⅲ-(AT-Ⅲ)을 함유하는 용액으로 부터 사람 α1-안티카이모트립신(ACT)을 정제하는 방법에 관한 것이다. 분리된 ACT는 시험관내 억제능을 가지며 강력한 치료적 용도를 갖는다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 사람혈장으로부터 바람직한 출발물질(콜 분획 Ⅳ-1페이스트현탁액)을 어떻게 분획화 시키는지를 나타내는, 일반화시킨 흐름도이다.
제2도는 ACT정제 과정의 바람직한 단계를 나타내는 흐름도이다.
Claims (9)
- (A)실질적으로 모든 α1-안티카이모트립신(ACT)을 흡착시키는 pH 및 전도도의 조건하에, α1-안티카이모트트립신, α1-프로테이나제 억제제(PI) 및 안티-트롬빈 Ⅲ-(AT-Ⅲ)의 혼합물의 수성 현탁액을 흡착제와 접촉시키는 단계; (B)실질적으로 모든 PI 및 AT-Ⅲ를 용출시키기 충분한 pH 및 전도도의 조건하에 흡착제를 세척시키는 단계 및 (C)흡착제로부터 ACT를 용출시키는 단계를 포함하여, 상기 α1-안티카이모트립신, α1-프로테이나제 억제제 및 안티-트롬빈 Ⅲ의 혼합물로부터 α1-안티카이모트립신을 분리시키는 방법.
- 제1항에 있어서, ACT를 흡착시키기에 충분한 조건하에 단계 (C)의 용출 생성물을 DNA-셀룰로즈와 접촉시키고 DNA-셀룰로즈부터 ACT를 용출시키기에 충분한 조건하에서 용출시킴을 포함하는 방법.
- (A)ACT, PI 및 AT-Ⅲ을 포함하는 수용액을 수득하는 단계; (B)이 용액을, ACT, PI 및 AT-Ⅲ을 흡착시키기 충분한 전도도 및 pH에서 이온 교환 수지와 접촉시키는 단계; (C)실질적으로 모든 PI 및 AT-Ⅲ를 용출시키기 충분한 pH 및 전도도의 조건하에서 흡착제를 세척하는 단계; (D)수지로부터 ACT를 용출시켜 용출액을 형성시키는 단계; (E)상기 용출액을, ACT를 흡착시키기 충분한 pH 및 조건하에서 DNA-셀룰로즈와 접촉시키는 단계 및 (F)DNA-셀룰로즈로부터 ACT를 용출시키는 단계를 포함하여, 사람의 ACT 및 사람의 α1-프로테이나제 억제제(PI) 및 사람의 안티-트롬빈 Ⅲ-(AT-Ⅲ)의 혼합물로부터 사람의 α1-안티카이모트립신(ACT)를 제조하는 방법.
- 제3항에 있어서, 단계(A)의 용액이 콘 분획 Ⅳ-1 페이스트 현탁액인 방법.
- 제3항에 있어서, 단계(B)의 이온 교환 수지가 음이온 교환 수지이고 용액의 pH가 약 6.5이며 전도도가 약 1.0 내지 2.5㎜ho/㎝인 방법.
- 제3항에 있어서, 단계(C)의 세척을, pH 약 6.5 및 전도도 7.0 내지 7.8㎜ho/㎝인 수용액으로 수행하는 방법.
- 제3항에 있어서, 단계(E)의 접촉을, pH가 약 6.8이고 전도도가 1.0 내지 2.0㎜ho/㎝인 용액을 사용하여 수행하는 방법.
- 순도가 90% 이상이고, 델마르 등의 어널리시스 바이오켐[DelMar et al, Anal, Biochem, 99:316(1979)]에 기술된 카텝신 지(Cathepsin G)분석법을 사용한 활성이 1.0㎎/총 단백질 ㎎을 초과하는 고도로 정제된 α1-안티카이모트립신 생성물.
- 제 8항에 있어서 약제학적으로 허용되는 담체중에 존재하는 생성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/282,860 | 1994-07-29 | ||
US08/282,860 US5561108A (en) | 1994-07-29 | 1994-07-29 | Preparation of α1 -antichymotrypsin |
US08/282860 | 1994-07-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR960004367A true KR960004367A (ko) | 1996-02-23 |
KR100433115B1 KR100433115B1 (ko) | 2004-08-30 |
Family
ID=23083438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019950022667A KR100433115B1 (ko) | 1994-07-29 | 1995-07-28 | α1-안티카이모트립신의제조방법 |
Country Status (12)
Country | Link |
---|---|
US (1) | US5561108A (ko) |
EP (1) | EP0694562B1 (ko) |
JP (1) | JP3693391B2 (ko) |
KR (1) | KR100433115B1 (ko) |
CN (1) | CN1175102C (ko) |
AT (1) | ATE197461T1 (ko) |
CA (1) | CA2154982C (ko) |
DE (1) | DE69519338T2 (ko) |
DK (1) | DK0694562T3 (ko) |
ES (1) | ES2151570T3 (ko) |
GR (1) | GR3035340T3 (ko) |
PT (1) | PT694562E (ko) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPP751198A0 (en) * | 1998-12-04 | 1999-01-07 | Csl Limited | Purification of A1-proteinase inhibitor |
US20090047325A1 (en) * | 1999-04-30 | 2009-02-19 | Neurotrophincell Pty. Limited | Xenotransplant for cns therapy |
DK1176970T3 (da) * | 1999-04-30 | 2010-09-20 | Neurotrophincell Pty Ltd | Xenotransplantat til CNS-terapi |
US20050265977A1 (en) * | 1999-04-30 | 2005-12-01 | Elliott Robert B | Xenotransplant for CNS therapy |
ATE341335T1 (de) * | 2000-01-20 | 2006-10-15 | Diabcell Pty Ltd | Präparation und xenotransplantation von inseln aus schweinen |
EP1333846B1 (en) * | 2000-10-17 | 2012-04-18 | Diabcell Pty Limited | Preparation and xenotransplantation or porcine islets |
NZ515310A (en) * | 2001-11-07 | 2004-08-27 | Diabcell Pty Ltd | Methods of treatment and delivery modes |
CN1791670A (zh) * | 2003-06-24 | 2006-06-21 | 戴伯塞尔有限公司 | 用于异种移植的用猪支持细胞培养的猪胰岛 |
NZ540597A (en) * | 2005-06-08 | 2007-02-23 | Neurotrophincell Pty Ltd | A method for preventing the onset of type I diabetes comprising administering an implantable composition comprising living choroid plexus cells |
CN103160486A (zh) * | 2013-04-02 | 2013-06-19 | 黑龙江迪龙制药有限公司 | 一种猪凝血酶的制备方法 |
CN110964707A (zh) * | 2019-12-31 | 2020-04-07 | 江西浩然生物制药有限公司 | 一种糜蛋白酶的提取纯化方法 |
CN112062833A (zh) * | 2020-10-09 | 2020-12-11 | 国药集团武汉血液制品有限公司 | 一种从血浆组分ⅳ沉淀中提取人血白蛋白的方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0067293B1 (en) * | 1981-05-01 | 1986-06-25 | Medical Research Institute of San Francisco | Method for isolating alpha-1-antitrypsin |
US4379087A (en) * | 1982-06-17 | 1983-04-05 | Cutter Laboratories, Inc. | Method of preparing alpha-1-proteinase inhibitor |
US5079336A (en) * | 1989-06-23 | 1992-01-07 | The Trustees Of The University Of Pennsylvania | α-1-antichymotrypsin, analogues and methods of production |
-
1994
- 1994-07-29 US US08/282,860 patent/US5561108A/en not_active Expired - Lifetime
-
1995
- 1995-07-19 DE DE69519338T patent/DE69519338T2/de not_active Expired - Lifetime
- 1995-07-19 DK DK95111304T patent/DK0694562T3/da active
- 1995-07-19 PT PT95111304T patent/PT694562E/pt unknown
- 1995-07-19 AT AT95111304T patent/ATE197461T1/de active
- 1995-07-19 EP EP95111304A patent/EP0694562B1/en not_active Expired - Lifetime
- 1995-07-19 ES ES95111304T patent/ES2151570T3/es not_active Expired - Lifetime
- 1995-07-26 JP JP20935195A patent/JP3693391B2/ja not_active Expired - Fee Related
- 1995-07-28 CN CNB951152335A patent/CN1175102C/zh not_active Expired - Fee Related
- 1995-07-28 KR KR1019950022667A patent/KR100433115B1/ko not_active IP Right Cessation
- 1995-07-28 CA CA002154982A patent/CA2154982C/en not_active Expired - Fee Related
-
2001
- 2001-02-01 GR GR20010400164T patent/GR3035340T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
ES2151570T3 (es) | 2001-01-01 |
CN1175102C (zh) | 2004-11-10 |
DK0694562T3 (da) | 2001-01-02 |
KR100433115B1 (ko) | 2004-08-30 |
EP0694562B1 (en) | 2000-11-08 |
CA2154982A1 (en) | 1996-01-30 |
GR3035340T3 (en) | 2001-05-31 |
AU2714395A (en) | 1996-02-08 |
CN1133885A (zh) | 1996-10-23 |
JPH08176197A (ja) | 1996-07-09 |
PT694562E (pt) | 2001-04-30 |
EP0694562A1 (en) | 1996-01-31 |
CA2154982C (en) | 2008-03-18 |
ATE197461T1 (de) | 2000-11-11 |
JP3693391B2 (ja) | 2005-09-07 |
AU700921B2 (en) | 1999-01-14 |
US5561108A (en) | 1996-10-01 |
DE69519338D1 (de) | 2000-12-14 |
DE69519338T2 (de) | 2001-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR960007617A (ko) | 새로운 크로마토그래피 분리조건을 이용한 α-1 프로테이나제 억제제의 정제방법 | |
KR960004367A (ko) | α1-안티카이모트립신의 제조방법 | |
AU1577795A (en) | Endotoxin reduction or removal process | |
ES2103309T3 (es) | Proceso cromatografico en fase invertida. | |
SE9603068D0 (sv) | Process for purifying a protein | |
AU591397B2 (en) | Method of preparing alpha-1-proteinase inhibitor | |
EP0669342B1 (de) | Verfahren zur Isolierung und Reinigung Vitamin K-abhängiger Proteine | |
Glaser et al. | The isolation of alpha-1-protease inhibitor by a unique procedure designed for industrial application | |
CA2210990A1 (en) | New combined process for the purification of vancomycin hydrochloride | |
Owen et al. | Evidence for an ester bond between thrombin and heparin cofactor | |
EP0282363A3 (en) | Method for preparation of a concentrate of alpha-1-antitrypsin from a human plasma fraction, and its use as a pharmaceutical | |
CA2274241A1 (en) | A process for purifying apolipoprotein a or apolipoprotein e from human plasma | |
CA2178208A1 (en) | Purification of vitamin-k dependent proteins by membrane chromatography | |
Legrand et al. | Purification of platelet proteases: activation of proelastase by a trypsin-like enzyme | |
CA2058453A1 (en) | Chymosin recovery and purification | |
JPS54138189A (en) | Separation and purification of urokinase | |
Wilkinson et al. | Affinity Chromatographic Separations of Chemically Modified α-Chymotrypsins from α-Chymotrypsin | |
ES2162117T3 (es) | Procedimiento cromatografico en fase inversa. | |
JPS5572145A (en) | Enzyme-adsorbent and purification of enzyme | |
Virupaksha et al. | Affinity chromatography of Sorghum acid protease | |
JPS5537129A (en) | Urokinase adsorbent, and preparation of high purity urokinase using the same | |
Ho et al. | A simple purification of calmodulin by reversed phase chromatography with hydrophobic polymer 3520 | |
JPS5750924A (en) | Purification of pancreatic enzyme, kallikrein | |
KR940000479A (ko) | 안티트롬빈-ⅲ의 제조방법 | |
JPS61234792A (ja) | マウスインタ−フエロンの精製法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20110512 Year of fee payment: 8 |
|
LAPS | Lapse due to unpaid annual fee |